Fisher Asset Management LLC Sells 65,153 Shares of Novo Nordisk A/S (NYSE:NVO)

Fisher Asset Management LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 0.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,305,474 shares of the company's stock after selling 65,153 shares during the quarter. Fisher Asset Management LLC owned approximately 0.30% of Novo Nordisk A/S worth $1,584,283,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of NVO. International Assets Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the period. DSM Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock valued at $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $98,765,000. Marshall Wace LLP raised its holdings in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company's stock valued at $98,696,000 after acquiring an additional 689,441 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $41,646,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on NVO shares. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $144.50.

Novo Nordisk A/S Trading Down 0.5 %

NVO traded down $0.50 on Monday, hitting $104.56. 4,293,571 shares of the company were exchanged, compared to its average volume of 4,509,882. The firm has a fifty day simple moving average of $114.83 and a two-hundred day simple moving average of $128.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The stock has a market capitalization of $469.22 billion, a PE ratio of 33.84, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.